Nature medicine reports agenus' novel immunotherapy demonstrates clinical activity against a deadly form of colorectal cancer on the rise in americans under 50

Lexington, mass.--(business wire)--agenus has published results from a groundbreaking clinical trial in nature medicine, revealing the potential of a novel immunotherapy combination for treating microsatellite stable metastatic colorectal cancer (mss mcrc), a cancer type historically resistant to immunotherapy. this pioneering research, led by an international team of oncologists, focuses on the efficacy and safety of botensilimab (bot), an fc-enhanced anti-ctla-4 antibody, in combination with.
AGEN Ratings Summary
AGEN Quant Ranking